ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rifaximin

Also written as “Rifaximin 200 mg Tablet”, “Low Dose Rifaximin ER” and “High Dose Rifaximin ER”.

Its studies are mostly in Diarrhea · Hepatic Encephalopathy · Rosacea · Anemia, Sickle Cell · Crohn Disease, led by 4 companies.

Drug pageRifaximin: every studyAll 150 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 16, 201322 company-led studies, 1 open or runningNext primary completion: Apr 20, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companiesits history only161 open or runningphase 4since Apr 16, 2013Dec 22, 2005Apr 20, 2027phase 4 · NCT07285785
Alfasigmaits history only40 open or runningphase 2since Feb 19, 2015Feb 19, 2015none ahead
Novartis10 open or runningphase 3since Sep 29, 2016Sep 29, 2016none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Jul 9, 2015Jul 9, 2015none ahead

Also a collaborator on its studies: bioRASI, Cromsource and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 29, 2016First study: phase 3 study in DiarrheaFirst studyNCT02920242 · 28 enrolled · Mexico

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule

Studies

The one study Novartis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02920242Diarrhea · Mexico3TerminatedMay 23, 201728

How it is read

Names in the registry

  • “Rifaximin”, 12 entries
  • “Rifaximin 200 mg Tablet”, 1 entry
  • “Low Dose Rifaximin ER”, 1 entry
  • “High Dose Rifaximin ER”, 1 entry
  • “Rifaximin delayed release tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.